Akebia Therapeutics has struck a deal for Q32 Bio’s deprioritized complement | Akebia Therapeutics has struck a deal for Q32 ...

Makary announced in May that he intended for the FDA to fully integrate generative AI into its work by the end of June; that ...

Angelini’s investments will be made through its Angelini Ventures arm. EIB and Angelini plan to support between seven and 10 ...

Regeneron is adding its name to Tessera Therapeutics’ unique in vivo gene writing program, inking a deal that lets it in on a ...

Belite linked tinlarebant to a 35.7% reduction in lesion growth rate versus placebo, achieving the study’s primary endpoint.

Though artificial intelligence has long made a name for itself in imaging—with hundreds of programs able to automate separate ...

Protego Biopharma is gearing up to bring its amyloid light-chain (AL) amyloidosis prospect into pivotal testing using its new ...

Researchers said they have uncovered a novel sign of chronic stress and its damaging effects on the body by using an ...